During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.

A 'Seràgnoli' Institute of Hematology Bologna University School of Medicine Bologna Italy

Centre de Recherches en Cancerologie de Toulouse CRCT Institut National de la Sante et de la Recherche Medicale Université Toulouse Toulouse France

Department of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Athens Greece

Department of Haematology Saint Antoine Hospital University Pierre and Marie Curie and INSERM UMRs 938 Paris France

Department of Hematology Amyloidosis and Myeloma Unit Hospital Clínic de Barcelona Spain

Department of Hematology and Oncology University of Freiburg Medical Center Freiburg Germany

Department of Hematology and Oncology University of Tuebingen Tuebingen Germany

Department of Hematology Clinica Universidad de Navarra Centro de Investigación Médica Aplicada IDISNA CIBERONC Pamplona Spain

Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands

Department of Hematology Lille University Hospital Lille France

Department of Hematology Newcastle University Newcastle UK

Department of Hematology Sahlgrenska Hospital Gothenburg Sweden

Department of Hematology St Olavs Hospital and IKOM NTNU Trondheim Norway

Department of Hematology University Hospital Leuven Catholic University Leuven Leuven Belgium

Department of Hematology University Hospital of Liège Liège Belgium

Department of Hematology University Hospital University of Nantes Nantes France

Department of Hematology VU University Medical Center Amsterdam The Netherlands

Department of Internal Medicine 2 University Hospital of Wuerzburg Wuerzburg Germany

Department of Medicine Ankara University Ankara Turkey

Department of Oncology and Hematology Cantonal Hospital St Gallen St Gallen Switzerland

Division of Hematology Citta della Salute e della Scienza University of Torino Torino Italy

Faculty of Medicine University Hospital Ostrava University of Ostrava Ostrava Czech Republic

Hospital Universitario de Salamanca Instituto Biosanitario de Salamanca Salamanca Spain

Leeds Institute of Cancer and Pathology University of Leeds Leeds UK

Myeloma Group The Institute of Cancer Research ICR London UK

Myeloma Unit Division of Hematology Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino University of Torino Torino Italy

National Center for Tumor Diseases Heidelberg Medical University Heidelberg Germany

Service d'Hématologie et Thérapie Cellulaire PRC and Inserm CIC1402 Hospital de la Miléterie Poitiers France

Wilhelminen Cancer Research Institute Vienna Austria

Zobrazit více v PubMed

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Multiple Myeloma. Version 1.2018. 2017. https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed 03 Oct 2017.

International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. Clinical safety data management: definitions and standards for expedited reporting. E2A. 1994. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf. Accessed 5 Dec 2016.

Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32:587–600. doi: 10.1200/JCO.2013.48.7934. PubMed DOI PMC

Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R, et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia. 2014;28:981–92. doi: 10.1038/leu.2013.293. PubMed DOI

Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blade J, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117:6063–73. doi: 10.1182/blood-2011-02-297325. PubMed DOI PMC

Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100:1254–66. doi: 10.3324/haematol.2014.117176. PubMed DOI PMC

National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections. Version 1.2018. December 1. 2017. https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf. Accessed 11. February 2018.

Snowden JA, Ahmedzai SH, Ashcroft J, D’Sa S, Littlewood T, Low E, et al. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol. 2011;154:76–103. doi: 10.1111/j.1365-2141.2011.08574.x. PubMed DOI

Dispenzieri A, Lacy MQ, Greipp PR. Multiple myeloma. In: Gertz MA, Greipp PR, editors. Hematologic malignancies: multiple myeloma and related plasma cell disorders. Berlin Heidelberg: Springer-Verlag; 2004. p. 55–109.

European Medicines Agency. Thalidomide celgene: EPAR - product information. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000823/WC500037050.pdf. Accessed 10 Nov 2016.

European Medicines Agency. Revlimid: EPAR - product information. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000717/WC500056018.pdf. Accessed 03 Oct 2017.

European Medicines Agency. Imnovid: EPAR - product information. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000717/WC500056018.pdf. Accessed 03 Oct 2017.

United States Food and Drug Administration. Thalidomide celgene: label information. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020785s051lbl.pdf. Accessed 10 Nov 2016.

United States Food and Drug Administration. Revlimid: label information. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021880s051lbl.pdf. Accessed 03 Oct 2017.

United States Food and Drug Administration. Pomalyst: label information. 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204026s012s014lbl.pdf. Accessed 03 Oct 2017.

Johnson DC, Corthals SL, Walker BA, Ross FM, Gregory WM, Dickens NJ, et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol. 2011;29:797–804. doi: 10.1200/JCO.2010.28.0792. PubMed DOI

Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2006;132:584–93. doi: 10.1111/j.1365-2141.2005.05914.x. PubMed DOI

Kapoor P, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia. 2011;25:689–96. doi: 10.1038/leu.2010.313. PubMed DOI

Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, et al. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. 2013;98:87–94. doi: 10.3324/haematol.2012.067058. PubMed DOI PMC

Mateos MV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev. 2010;36:S24–32. doi: 10.1016/S0305-7372(10)70009-8. PubMed DOI

Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906–17. doi: 10.1056/NEJMoa1402551. PubMed DOI

Pawlyn C, Khan MS, Muls A, Sriskandarajah P, Kaiser MF, Davies FE, et al. Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood. 2014;124:2467–8. doi: 10.1182/blood-2014-06-583302. PubMed DOI

Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366:1759–69. doi: 10.1056/NEJMoa1112704. PubMed DOI

Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782–91. doi: 10.1056/NEJMoa1114138. PubMed DOI

McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770–81. doi: 10.1056/NEJMoa1114083. PubMed DOI PMC

Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S, et al. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood. 2012;120:1597–1600. doi: 10.1182/blood-2012-04-421883. PubMed DOI PMC

Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15:333–42. doi: 10.1016/S1470-2045(13)70609-0. PubMed DOI

Jones JR, Cairns DA, Gregory WM, Collett C, Pawlyn C, Sigsworth R, et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016;6:e506. doi: 10.1038/bcj.2016.114. PubMed DOI PMC

Chen N, Zhou S, Palmisano M. Clinical pharmacokinetics and pharmacodynamics of lenalidomide. Clin Pharmacokinet. 2017;56:139–52. doi: 10.1007/s40262-016-0432-1. PubMed DOI PMC

European Medicines Agency. Velcade: EPAR - product information. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000539/WC500048471.pdf. Accessed 3 Dec 2016.

United States Food and Drug Administration. Velcade: label information. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021602s043lbl.pdf. Accessed 03 Oct 2017.

European Medicines Agency. Kyprolis: EPAR - product information. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003790/WC500197692.pdf. Accessed 03 Oct 2017.

United States Food and Drug Administration. Kyprolis: label information. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202714s016lbl.pdf. Accessed 03 Oct 2017.

United States Food and Drug Administration. Ninlaro: label information. 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208462s001lbl.pdf. Accessed 03 Oct 2017.

European Medicines Agency. Ninlaro: EPAR - product information. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003844/WC500217620.pdf. Accessed 03 Oct 2017.

San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15:1195–206. doi: 10.1016/S1470-2045(14)70440-1. PubMed DOI

European Medicines Agency. Farydak: EPAR - product information. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003725/WC500193298.pdf. Accessed 03 Oct 2017.

United States Food and Drug Administration. Farydak: label information. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf. Accessed 03 Oct 2017.

European Medicines Agency. Empliciti: EPAR - product information. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003967/WC500206673.pdf. Accessed 3 Oct 2017.

United States Food and Drug Administration. Empliciti: label information. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761035s005lbl.pdf. Accessed 03 Oct 2017.

European Medicines Agency. Darzalex: EPAR - product information. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004077/WC500207296.pdf. Accessed 5 Dec 2016.

United States Food and Drug Administration. Darzalex: label information. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761036s005lbl.pdf. Accessed 03 Oct 2017.

van de Donk NW, Otten HG, El Haddad O, Axel A, Sasser AK, Croockewit S, et al. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA) Clin Chem Lab Med. 2016;54:1105–9. PubMed

Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garcia-Sanchez O, Bottcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094–103. doi: 10.1038/leu.2017.29. PubMed DOI PMC

De Stefano V, Za T, Rossi E. Venous thromboembolism in multiple myeloma. Semin Thromb Hemost. 2014;40:338–47. doi: 10.1055/s-0034-1370793. PubMed DOI

Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414–23. doi: 10.1038/sj.leu.2405062. PubMed DOI

Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med. 2002;162:2605–9. doi: 10.1001/archinte.162.22.2605. PubMed DOI

ten Cate-Hoek AJ, Weitz JI, Gailani D, Meijer K, Philippou H, Bouman AC, et al. Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS) Thromb Res. 2015;136:S13–18. doi: 10.1016/j.thromres.2015.07.036. PubMed DOI PMC

Delforge M, Blade J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010;11:1086–95. doi: 10.1016/S1470-2045(10)70068-1. PubMed DOI

Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817–25. doi: 10.1182/blood-2012-05-425934. PubMed DOI PMC

Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011;17:2734–43. doi: 10.1158/1078-0432.CCR-10-1950. PubMed DOI

Kelly JJ. The evaluation of peripheral neuropathy. Part I: clinical and laboratory evidence. Rev Neurol Dis. 2004;1:133–40. PubMed

Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63:419–37. doi: 10.3322/caac.21204. PubMed DOI

Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012;26:595–608. doi: 10.1038/leu.2011.346. PubMed DOI

Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431–40. doi: 10.1016/S1470-2045(11)70081-X. PubMed DOI

World Health Organization. WHO’s cancer pain ladder for adults. 2016. http://www.who.int/cancer/palliative/painladder/en/. Accessed 20 Dec 2016.

Stacey BR. Management of peripheral neuropathic pain. Am J Phys Med Rehabil. 2005;84:S4–16. PubMed

Krone A, Reuther P, Fuhrmeister U. Autonomic dysfunction in polyneuropathies: a report on 106 cases. J Neurol. 1983;230:111–21. doi: 10.1007/BF00313638. PubMed DOI

Lee WS, Kim DH, Shin SH, Woo SI, Kwan J, Park KS, et al. Complete atrioventricular block secondary to bortezomib use in multiple myeloma. Yonsei Med J. 2011;52:196–8. doi: 10.3349/ymj.2011.52.1.196. PubMed DOI PMC

Figueroa JJ, Basford JR, Low PA. Preventing and treating orthostatic hypotension: as easy as A, B, C. Cleve Clin J Med. 2010;77:298–306. doi: 10.3949/ccjm.77a.09118. PubMed DOI PMC

Basler M, Lauer C, Beck U, Groettrup M. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol. 2009;183:6145–50. doi: 10.4049/jimmunol.0901596. PubMed DOI

Advisory Committee for Immunization Practices. Vaccine-specific recommendations. 2016. https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/. Accessed 30 Dec 2016.

The University of Hong Kong. VZV vaccine for hematopoietic stem cell transplantation (VZIDST). 2015. https://clinicaltrials.gov/ct2/show/study/NCT02329457. Accessed 30 Dec 2016.

Stadtmauer EA, Sullivan KM, Marty FM, Dadwal SS, Papanicolaou GA, Shea TC, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124:2921–9. doi: 10.1182/blood-2014-04-573048. PubMed DOI PMC

Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med. 2002;347:26–34. doi: 10.1056/NEJMoa013441. PubMed DOI

Redman RL, Nader S, Zerboni L, Liu C, Wong RM, Brown BW, et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis. 1997;176:578–85. doi: 10.1086/514077. PubMed DOI

Hahn M, Schnitzler P, Schweiger B, Kunz C, Ho AD, Goldschmidt H, et al. Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma. Haematologica. 2015;100:e285–288. doi: 10.3324/haematol.2014.116772. PubMed DOI PMC

Teng CJ, Liu HT, Liu CY, Hsih CH, Pai JT, Gau JP, et al. Chronic hepatitis virus infection in patients with multiple myeloma: clinical characteristics and outcomes. Clinics. 2011;66:2055–61. doi: 10.1590/S1807-59322011001200010. PubMed DOI PMC

Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84:274–80. doi: 10.4065/84.3.274. PubMed DOI PMC

MacFarlane LL, Simmons MM, Hunter MH. The use of corticosteroids in the management of herpes zoster. J Am Board Fam Pract. 1998;11:224–8. doi: 10.3122/15572625-11-3-224. PubMed DOI

Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Neumann S, Penack O, et al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) Ann Hematol. 2015;94:1441–50. doi: 10.1007/s00277-015-2447-3. PubMed DOI PMC

Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107–13. doi: 10.3324/haematol.2014.107714. PubMed DOI PMC

Teh BW, Harrison SJ, Worth LJ, Spelman T, Thursky KA, Slavin MA. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol. 2015;171:100–8. doi: 10.1111/bjh.13532. PubMed DOI

Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–52. doi: 10.1056/NEJMoa1411321. PubMed DOI

Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for immunoglobulin replacement therapy in multiple myeloma. Lancet. 1994;343:1059–63. doi: 10.1016/S0140-6736(94)90180-5. PubMed DOI

Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma. 2009;50:764–72. doi: 10.1080/10428190902856824. PubMed DOI

van de Donk NW, Gorgun G, Groen RW, Jakubikova J, Mitsiades CS, Hideshima T, et al. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res. 2012;4:253–68. PubMed PMC

Lee MJ, Wickner P, Fanning L, Schlossman R, Richardson P, Laubach J, et al. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. Br J Haematol. 2014;167:127–31. doi: 10.1111/bjh.12925. PubMed DOI

Westergaard H. Bile Acid malabsorption. Curr Treat Options Gastroenterol. 2007;10:28–33. doi: 10.1007/s11938-007-0054-7. PubMed DOI

Andreyev HJ, Davidson SE, Gillespie C, Allum WH, Swarbrick E, British Society of G et al. Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. Gut. 2012;61:179–92. PubMed PMC

Benson AB, 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, Jr., et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22:2918–26. doi: 10.1200/JCO.2004.04.132. PubMed DOI

Siegel DS, Weisel KC, Dimopoulos MA, Baz R, Richardson P, Delforge M, et al. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leuk Lymphoma. 2016;57:2833–8. doi: 10.1080/10428194.2016.1177181. PubMed DOI

Rosenthal A, Luthi J, Belohlavek M, Kortum KM, Mookadam F, Mayo A, et al. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 2016;6:e384. doi: 10.1038/bcj.2015.112. PubMed DOI PMC

Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Ziogas D, Eleutherakis-Papaiakovou E, et al. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv. 2017;1:449–54. doi: 10.1182/bloodadvances.2016003269. PubMed DOI PMC

Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos MA, Hajek R, et al. Phase 3 study (CLARION) of carfilzomib, melphalan, prednisone (KMP) v bortezomib, melphalan, prednisone (VMP) in newly diagnosed multiple myeloma (NDMM). 16th International Myeloma Workshop: New Delhi; 2017. p. OP-044.

Russell SD, Lyon A, Lenihan DJ, Moreau P, Joshua D, Chng W-J, et al. Serial echocardiographic assessment of patients (Pts) with relapsed multiple myeloma (RMM) receiving carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd): a Substudy of the phase 3 Endeavor trial (NCT01568866). Blood. 2015;126: abstract 4250.

Jakubowiak AJ, DeCara JM, Mezzi K. Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies. Hematology. 2017;22:585–91. doi: 10.1080/10245332.2017.1328165. PubMed DOI

Mikhael J. Management of carfilzomib-associated cardiac adverse events. Clin Lymphoma Myeloma Leuk. 2016;16:241–5. doi: 10.1016/j.clml.2016.01.008. PubMed DOI

Lonial S, Jakubowiak AJ, Jagannath S, Raab MS, Facon T, Vij R, et al. A phase 2 study of elotuzumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma. Blood. 2011;118:303–303.

Voorhees PM, Weiss BM, Usmani S, Feng H, Uhlar C, Khan I, et al. Management of infusion-related reactions following daratumumab monotherapy in patients with at least 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius) Blood. 2015;126:1829–1829.

Chari A, Mark TM, Krishnan A, Stockerl-Goldstein K, Usmani SZ, Londhe A, et al. Use of montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in United States Patients with relapsed or refractory multiple myeloma. ASH: San Diego; 2016. abstract 2142. PubMed PMC

Usmani SZ, Nahi H, Mateos M-V, Lokhorst HM, Chari A, Kaufman JL, et al. Open-label, multicenter, dose escalation phase 1b study to assess the subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (PAVO). ASH: San Diego, CA; 2016. abstract 1149.

Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–238. doi: 10.1016/j.bbmt.2009.06.019. PubMed DOI PMC

Cheuk DK, Chiang AK, Lee TL, Chan GC, Ha SY. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database Syst Rev. 2011; CD006505. PubMed

Boehmer LM, Waqar SN, Govindan R. Influenza vaccination in patients with cancer: an overview. Oncology. 2010;24:1167–70. PubMed

Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF, et al. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults>=50 years of age. J Infect Dis. 2013;208:1953–61. doi: 10.1093/infdis/jit365. PubMed DOI

Mallet V, van Bommel F, Doerig C, Pischke S, Hermine O, Locasciulli A, et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis. 2016;16: 606–17. PubMed

Wanchoo R, Abudayyeh A, Doshi M, Edeani A, Glezerman IG, Monga D, et al. Renal toxicities of novel agents used for treatment of multiple myeloma. Clin J Am Soc Nephrol. 2017;12:176–89. doi: 10.2215/CJN.06100616. PubMed DOI PMC